Single-Cell MRD Assessment in AML: Advancing Beyond Standard Care
- Identify the limitations of standard-ofcare AML MRD assays: Understand how bulk NGS and multiparameter flow cytometry (MFC) can yield false negatives and false positives due to complex clonal evolution, phenotypic shifts, and overlapping immunophenotypes
- Evaluate comparative clinical data: Single-cell AML MRD clinical study data demonstrates how single-cell multiomics achieves superior sensitivity (93%) compared to traditional flow cytometry (43%) and molecular methods (71%), offering a more accurate stratification of relapse-free survival
- Redefining the future of AML MRD clinical evaluation: Single-cell multi-omics in AML MRD analysis provides the clinical evidence required to anticipate relapse better, establish deciding factors for interventions like treatment consolidation, targeted therapeutic pivoting, and clinical trial stratification